Brazilian healthtech startup Central da Visão raises R$10M to expand affordable eye surgeries

Brazil-based healthtech startup Central da Visão has secured a cool R$10 million (US$1.7 million) to help provide access to affordable eye surgeries across the country.

Central da Visão raised the amount in a Series A funding round led by HT3 Investimentos, part of the H. Egídio Group in the pharmaceutical sector. The funding round also attracted investment from Hangar 8 Capital, Gávea Angels, 4AM Capital, Sororitê Angel Network, and Columbia Ventures Brazil, with Harvard Angels of Brazil and GV Angels finalizing their involvement.

Central da Visão, founded in 2017 by Marta Luconi (CEO), Guilherme Almeida Prado, and Ronaldo Abati, focuses on making eye surgeries more accessible. By utilizing unused space in private clinics, the company offers lower-cost ophthalmological surgeries, opening doors to a broader range of patients. 

Since its launch in São Paulo, the healthtech has expanded to more than 50 affiliated clinics across 14 states, with over 200 ophthalmologists on board. In 2023, Central da Visão carried out surgeries valued at R$27 million, generating R$5.5 million in revenue.

For 2026, the company has set its sights on reaching 100,000 surgeries – making the new investment crucial as Central da Visão makes plans to advance its proprietary technology for patient care. 

The startup’s CRM system, Farol, handles over half a million monthly messages for a user base exceeding 300,000, supporting patients along their surgical journey.

“We’ve focused on the patient’s entire surgical experience, catering to the Out of Pocket market — people outside traditional private healthcare,” explains CTO Ronaldo Abati. “Farol helps us manage this individualized approach, ensuring a comprehensive care experience.”

CEO Marta Luconi adds that their model is highly scalable, leveraging technology to reach patients who often fall outside the coverage of Brazil’s public healthcare system.

“With over half a million people waiting for cataract surgeries alone, the demand is immense,” she explains. “Our aging population presents a significant growth opportunity, allowing us to expand into new cities and clinics where access to vision care is limited.”

Meanwhile, HT3 Investimentos’ investment in Central da Visão marks the H. Egídio Group’s first foray into startups focused on human health.

“For 37 years, we’ve served hospitals with pharmaceuticals and supplies. Now, we’re looking to meet the needs of patients directly,” HT3 Investimentos’ CEO Tiago Simon Egidio said in a statement.

With this infusion of capital, Central da Visão is poised to scale rapidly, aiming to bridge the gap between traditional healthcare and affordable, accessible surgical care across Brazil.

Share this Post:

Accessibility Toolbar